



UNIVERSITÀ
DEGLI STUDI
FIRENZE

FLORE

Repository istituzionale dell'Università degli Studi di Firenze

LMW-PTP modulates glucose metabolism in cancer cells

Questa è la Versione finale referata (Post print/Accepted manuscript) della seguente pubblicazione:

Original Citation:

LMW-PTP modulates glucose metabolism in cancer cells / Giulia Lori, Tania Gamberi, Paolo Paoli, Anna Caselli, Erica Pranzini, Riccardo Marzocchini, Alessandra Modesti, Giovanni Rauei. - In: BIOCHIMICA ET BIOPHYSICA ACTA-GENERAL SUBJECTS. - ISSN 0304-4165. - ELETTRONICO. - 1862:(2018), pp. 2533-2544. [10.1016/j.bbagen.2018.08.003]

Availability:

This version is available at: 2158/1137492 since: 2019-07-03T14:27:14Z

Published version:

DOI: 10.1016/j.bbagen.2018.08.003

Terms of use:

Open Access

La pubblicazione è resa disponibile sotto le norme e i termini della licenza di deposito, secondo quanto stabilito dalla Policy per l'accesso aperto dell'Università degli Studi di Firenze (<https://www.sba.unifi.it/upload/policy-oa-2016-1.pdf>)

Publisher copyright claim:

Conformità alle politiche dell'editore / Compliance to publisher's policies

Questa versione della pubblicazione è conforme a quanto richiesto dalle politiche dell'editore in materia di copyright.

This version of the publication conforms to the publisher's copyright policies.

(Article begins on next page)

LMW-PTP modulates glucose metabolism in cancer cells.

1
2 Giulia Lori[§], Tania Gamberi[§], Paolo Paoli, Anna Caselli, Erica Pranzini, Riccardo Marzocchini,
3 Alessandra Modesti and Giovanni Raugei*
4
5
6
7
8

9 Department of Experimental and Clinical Biomedical Sciences, University of Florence, Florence,
10 Italy
11
12
13
14
15
16
17
18
19
20
21
22
23

24 [§] These authors contributed equally to the work.
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40

41 * **Corresponding author:** Giovanni Raugei
42 **email:** giovanni.raugei@unifi.it
43 **Address:** viale G.B. Morgagni 50, 50134 Florence, Italy.
44 **Telephone:** +39 055 2751202
45 **Fax:** +39 055 4598305
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

Abstract

Background

Low Molecular Weight Phosphotyrosine Protein Phosphatase (LMW-PTP) is an enzyme involved not only in tumor onset and progression but also in type 2 diabetes. A recent review shows that LMW-PTP acts on several RTK (receptor tyrosine kinase) such as PDGFR, EGFR, EphA2, Insulin receptor. It is well described also its interaction with cSrc. It is noteworthy that most of these conclusions are based on the use of cell lines expressing low levels of LMW-PTP. The aim of the present study was to discover new LMW-PTP substrates in aggressive human tumors where the over-expression of this phosphatase is a common feature.

Methods

We investigated, by proteomic analysis, the protein phosphorylation pattern of A375 human melanoma cells silenced for LMW-PTP. Two-dimensional electrophoresis (2-DE) analysis, followed by western blot was performed using anti-phosphotyrosine antibodies, in order to identify differentially phosphorylated proteins.

Results

Proteomic analysis pointed out that most of the identified proteins belong to the glycolytic metabolism, such as ***α*-enolase, pyruvate kinase, glyceraldehyde-3-phosphate dehydrogenase and triosephosphate isomerase**, suggesting an involvement of LMW-PTP in glucose metabolism. Assessment of lactate production and oxygen consumption demonstrated that LMW-PTP silencing enhances glycolytic flux and slow down the oxidative metabolism. In particular, LMW-PTP expression affects PKM2 tyrosine-phosphorylation and nuclear localization, modulating its activity.

Conclusion

All these findings propose that tumor cells are subjected to metabolic reprogramming after LMW-PTP silencing, enhancing glycolytic flux, probably to compensate the inhibition of mitochondrial metabolism.

General significance

Our results highlight the involvement of LMW-PTP in regulating glucose metabolism in A375 melanoma cells.

Keywords

LMW-PTP; Glucose metabolism; PKM2; metabolic reprogramming of cancer cells.

1. Introduction

1 Low Molecular Weight Phosphotyrosine Protein Phosphatase (LMW-PTP) is an enzyme that has
2 been recognized to play a dual role in the cell, being involved not only in tumor onset and
3 progression but also in type 2 diabetes. As far as tumor is concerned, it has been reported that
4 ectopic over-expression of LMW-PTP in NIH3T3 fibroblasts engrafted in nude mice leads to the
5 formation of larger sarcomas [1]. Malentacchi et al., [2] demonstrated that LMW-PTP is over-
6 expressed in different human cancers, such as colon cancer and neuroblastoma and, also in pre-
7 neoplastic lesions of colon from rats treated with tumor inducing agents [3]. These data were
8 recently further confirmed by a study on a wide collection of specimens from prostate cancer [4].
9 Interestingly, its over-expression, in many cases, correlates with a worse prognosis and a reduced
10 survival. Moreover, it has been recently assessed that LMW-PTP is involved in the modulation of
11 apoptosis and acquisition of drug resistance: over-expression of LMW-PTP confers resistance to
12 vincristine in leukemic cells [5] and mediates malignant potential in colorectal cancer, inducing
13 drug resistance and enhancing cell mobility [6].

14 Very recently Lori et al., [7], further confirmed the oncogenic role of LMW-PTP, suggesting the
15 possibility of tumor treatment through LMW-PTP targeting: they demonstrated that using an
16 inhibitor of LMW-PTP it is possible, in A375 and PC3 cancer cells (both over-expressing LMW-
17 PTP) to enhance susceptibility to apoptosis induced by chemo-and radio-therapy. Together, these
18 evidences sustain a clear oncogenic role of LMW-PTP.

19 As far as type 2 diabetes is concerned, it is known that Insulin Receptor (IR) is a substrate of LMW-
20 PTP [8]. Being the IR negatively regulated by de-phosphorylation, it has been hypothesized that
21 LMW-PTP may be involved in this disease. In a very recent paper it has been assessed that negative
22 modulation of LMW-PTP in mice protect from fat-induced diabetes [9]. Another very recent paper
23 [10] shows the ability of LMW-PTP to control the glycolytic phenotype in a specific leukemia cell
24 line, suggesting that LMW-PTP may be involved also in the metabolic control of cancer cells.

25 Nowadays, many different substrates have been proposed for LMW-PTP, most of them collocated
26 in a logical panorama of the different LMW-PTP functions. A recent review [11], shows the
27 complexity of the LMW-PTP interactions in the cell, underlining particularly its action on several
28 RTK (receptor tyrosine kinase), such as PDGFR, EGFR, EphA2, Insulin receptor and others. In
29 addition, it is well described also its interaction with cSrc.

30 It should be noticed that most of the results were obtained using cell lines not expressing high levels
31 of LMW-PTP. Our idea was to use the A375 cell line, derived from a very aggressive human
32 melanoma, and expressing very high level of LMW-PTP. In this way, we aimed to select new
33 LMW-PTP substrates, particularly important in tumors over-expressing this tyrosine phosphatase.

1 To this purpose, we performed comparative phospho-proteomic analysis between A375 control
2 cells and cells silenced for LMW-PTP, to detect hyper-phosphorylated proteins, as putative targets
3 of LMW-PTP enzymatic activity. Our results pointed out an interesting aspect of LMW-PTP
4 functions, underling that this enzyme may have an important role in regulating oxidative
5 metabolism in cancer cells.
6
7

8 9 **2. Materials and Methods**

10 **2.1. Cell lines and transfection.**

11 A375, PC3, HT29, DU145 and MEC1 cells were purchased from ATCC (Manassas, USA).
12 Leukemia cells were cultured in Roswell Park Memorial Institute (RPMI 1640, Sigma-Aldrich, St.
13 Louis, USA). A375, PC3, HT29 and DU145 were cultured in Dulbecco's Modified Eagles Medium
14 (Euroclone). All media were supplemented with 10% fetal bovine serum, 100 U/ml penicillin, 100
15 mg/ml streptomycin (Sigma-Aldrich, St. Louis, USA). Cell lines were routinely tested for
16 Mycoplasma infection using Mycoalert, Mycoplasma Detention Kit (Lonza). 1x10⁵ cells/mL were
17 grown for 24h and then transiently transfected with LMW-PTP siRNA (Target sequence
18 CCCATAGTGCACACTTGTATA, final concentration 20 nm), using Hiperfect Transfection Reagent
19 (Qiagen) according to the manufacturer's instructions. To test the specificity of LMW-PTP
20 transfection, control cells were transfected with a Scramble Sequence (AllStars Negative Control
21 siRNA, final concentration 20nM, Qiagen). DU145 cells were transiently transfected with
22 pRcCMV-C12S-LMW-PTP expressing the dominant-negative (Dn) Cys-12 to Ser mutant of LMW-
23 PTP (Chiarugi et al., 1995). Briefly, 10 µg of plasmidic DNA was transfected using Lipofectamine
24 2000 (Invitrogen) according to the manufacturer's instructions.
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40

41 **2.2. Western blotting**

42 Cells were lysed on iced in 1X Laemmli buffer (0.5 M TrisHCl pH 6.8, 10% SDS, 20% glycerol, β-
43 mercaptoethanol, 0.1% bromophenol blue) and samples were boiled for 10 minutes. Cell extracts
44 were resolved by SDS-PAGE and transferred to PVDF membranes (BioRad). Membranes were
45 incubated overnight at 4°C with the appropriate primary antibody: rabbit polyclonal anti-LMW-PTP
46 were produced in our laboratory [7]. Annexin A1, PKM2, TIPS, GAPDH, α-Enolase, GLUT-1,
47 **Hexokinase** II, Lamin A/C and Actin were obtained from Santa Cruz Biotechnology. Anti-
48 phosphotyrosine, clone 4G10 were from Merck-Millipore. After washing in TPBS-Tween 20
49 (0.1%) membranes were incubated with the appropriate horseradish peroxidase-conjugated
50 secondary antibodies (Santa Cruz Biotechnology) for 1h. Proteins were detected using Clarity
51 Western ECL (Biorad) by **UVP ChemiDoc-it 500 Imaging System (DBA Analytik Jena US)**.
52
53
54
55
56
57
58
59
60
61
62
63
64
65

2.3. Immuno and co-immunoprecipitation

1
2 Cells (3×10^5) were seeded in 60 mm plates and transfected with LMW-PTP siRNA or Dn mutant.
3
4 After 28 h, cells were lysed for 20 min on ice in 300 μ L of RIPA buffer (50mM TrisHCl pH 7.5,
5 150 mM NaCl, 100 mM NaF, 2 mM EGTA, 1% triton X-100, 10 μ L/ml protease and phosphatase
6 inhibitor, Sigma). Lysates were centrifugated at 4°C, 14000 rpm for 15 min: supernatants were
7 collected. After protein quantification with Bradford Assay, 400 μ g of proteins were
8 collected. After protein quantification with Bradford Assay, 400 μ g of proteins were
9 immunoprecipitated overnight, at 4°C with the specific primary antibodies (1:100). Then Protein
10 A/G PLUS-Agarose (Santa Cruz) was added and incubated at 4°C for 1h. Immunocomplexes were
11 collected and analyzed by western blotting.
12
13
14
15
16
17

2.4. Extracellular Flux (XF) analysis (Seahorse technology)

18
19 The Oxygen Consumption Rate (OCR, pmolesO₂ consumed/min) and the ExtraCellular
20 Acidification Rate (ECAR, mpH/min) were determined by using the XF96 Extracellular Flux
21 Analyzer (Seahorse Bioscience) according to manufacturer's instructions. Cells were plated $1.5 \times$
22 10^4 cells/well on XF96-well microplates in standard medium. After one-day incubation, were
23 washed three times with an unbuffered assay medium (pH 7.4) and conditioned for 1 h at 37°C
24 without CO₂. After incubation, XF measurements was performed. A Seahorse XF Cell Mito Stress
25 Test was used to evaluate the mitochondrial function in different experimental conditions. Using
26 this kit, parameters of mitochondrial function were determined by directly measuring the OCR of
27 cells after the injection of specific drugs that target components of the ETC in the mitochondria.
28 The compounds (oligomycin, FCCP, and a mix of rotenone and antimycin A) were injected in
29 sequence to measure basal respiration, ATP-linked respiration, maximal respiration, and non-
30 mitochondrial respiration, respectively. Maximal respiratory capacity was then calculated by
31 subtracting the basal respiration values from maximal respiration values.
32
33
34
35
36
37
38
39
40
41
42
43
44

2.5. Lactate assay

45
46 Measurement of lactate production was determined using L-Lactic Acid (L-Lactate) colorimetric
47 assay from Megazyme, according to manufacturer's instruction. Briefly, medium culture was
48 collected and incubated in a buffer containing NAD⁺, D-GTP, and L-LDH. Measurements were
49 done at 340 nm by using a spectrophotometer.
50
51
52
53
54
55

2.6. Glucose uptake

56
57 Cells (1.8×10^6) were seeded in 35 mm dishes and transfected with siRNA. After 28 h, 1 μ L /ml
58 μ Ci/mL (U-14C) deoxy-D-Glucose (PerkinElmer) was added and dishes were incubated for 30 min
59
60
61
62
63
64
65

1
2 at 37°C. Then cells were washed twice with cold PBS and lysed with 0,1M NaOH. The amount of
3 (U-14C) deoxy-D-Glucose incorporated was evaluated by a scintillator analyzer (Tri-Carb 2800TR,
4 PerkinElmer).
5
6

7 **2.7. Gelatin zymography**

8
9 Conditioned media were collected and subjected to electrophoresis on 7.5% PAGE gels containing
10 0.1% gelatin. After electrophoresis the gel was washed twice with 2.5% triton X-100 and once with
11 Reaction Buffer (50mM Tris HCl, pH 7.5, 200 mM NaCl, 5mM CaCl₂). The gel was incubated
12 overnight at 37°C with fresh Reaction Buffer. Then gel was stained with 0.25 Coomassie Brilliant
13 Blue and destained (30% methanol and 10% acetic acid).
14
15
16
17
18
19

20 **2.8. Boyden Chamber assay**

21 Cell invasion was performed with 5×10^4 cells on 8- μ m-pore Transwells (Corning) coated with 50
22 μ g/cm² of reconstituted Matrigel. Cells were harvest, resuspended in serum-free medium and
23 placed in the upper compartment. In the lower chamber, 600 μ L of medium supplemented with
24 FBS was added as a chemoattractant. After the cells were incubated for 12 h at 37 °C in a 5% CO₂
25 atmosphere. Cells adhering to the lower surface were stained with Diff Quick staining kit. The
26 numbers of cells in 6 randomly selected fields in each well were counted.
27
28
29
30
31
32
33

34 **2.9. Two-dimensional electrophoresis (2-DE)**

35
36 A375 cells (3×10^5) were seeded in 100 mm plates and transfected with LMW-PTP siRNA or a
37 scramble sequence (control cells) as described above. After 28 h, cells were lysed for 20 min on ice
38 in 1 mL of RIPA buffer (50mM TrisHCl pH 7.5, 150 mM NaCl, 100 mM NaF, 2 mM EGTA, 1%
39 triton X-100, 10 μ L/ml protease and phosphatase inhibitor, Sigma). Lysates were centrifuged at 4°C,
40 8000g for 15 min and then supernatants were collected. The cells were sonicated (15 s) and protein
41 extracts were clarified by centrifugation at 8000g, 4°C for 15 min. For the first-dimension
42 electrophoresis, protein samples (80 μ g for Phospho-blot and 180 μ g for Coomassie-stained gels)
43 were applied to 110-mm pH 3–10 IPG® ReadyStrip (Bio-Rad, Hercules CA). The strips were then
44 actively rehydrated in the protein isoelectric focusing (IEF) cell (Bio-Rad) at 50 V for 18 h. The
45 isoelectric focusing was performed in increasing voltages as follows; 300 V for 1 h, then linear
46 gradient to 8000 V for 5 h and finally 20 000 V/h. For the second dimension, the IPG® Strips, were
47 equilibrated for 10 min in 50 mM Tris–HCl (pH 6.8) containing 6 M urea, 1% (w/v) sodium
48 dodecyl sulfate (SDS), 30% (v/v) glycerol, and 0.5% dithiothreitol, and then re-equilibrated for 15
49 min in the same buffer containing 4.5% iodoacetamide instead of dithiothreitol. Linear gradient
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

1 precast criterion Tris–HCl gels (8–16%) (Bio-Rad) were used to perform second dimension
2 electrophoresis. Precision Protein™ Standards (Bio-Rad, CA) were run along with the samples at
3 200 V for 65 min. For each sample (A375 cells transfected with LMW-PTP siRNA or the scramble
4 sequence) two 2-DE gels were performed. Gels with 180 µg of protein samples were stained by
5 colloidal Coomassie [12] to visualize protein spots; gels with 80 µg of protein samples was used to
6 phosphoprotein detection by western blot analysis.
7
8
9

10 **2.10. Immunodetection of tyrosine-phosphorylated proteins (2-D Phospho-blot)**

11
12 After running, 2-DE gels, with 80 ug of protein sample, were blotted on polyvinylidene fluoride
13 (PVDF) membrane. The PVDF membranes were incubated for 3 h at 4°C with the primary anti-
14 phosphotyrosine 4G10 IgG antibody (1:1,000 dilution). An enhanced chemiluminescence kit (GE
15 Healthcare) was used for detection by UVP ChemiDoc-it 500 Imaging System (DBA Analytik Jena
16 US).
17
18

19 For each cell specimen (A375 cells transfected with LMW-PTP siRNA or the scramble sequence)
20 three independent 2-DE experiments (both 2-DE colloidal Coomassie-stained gels and 2-D
21 phospho-blot) were performed (biological replicates). To minimize the variability between the
22 samples, from each 2-DE experiment, we carried out two technical replicates (two 2-DE colloidal
23 Coomassie- stained gels and two 2-D phospho-blot). Then, for each cell specimen a total of six
24 colloidal Coomassie-stained gels and six 2-D phospho-blot were analyzed. 2-DE gel and phospho-
25 blot images were digitized using the Epson expression 1680 PRO scanner and saved with a
26 resolution of 300 dpi and as 16-bit TIFF format. Computer-aided 2D image analysis was carried out
27 using ImageMaster 2D Platinum software v7.0 (GE Healthcare) on both 2-D colloidal Coomassie
28 gels (for differential expression analysis) and on 2-D phospho-blot (for differential
29 phosphorylation analysis). After automatic protein detection and matching, the gels were manually
30 corrected to remove wrongly assigned or duplicated spots and image artifacts. Relative spot volume
31 ($\%V = V_{\text{single spot}} / V_{\text{total spots}}$, where V is the integration of the optical density over the spot
32 area) was used during analysis to reduce experimental error. Spots detected in the 2-D phospho-
33 blot and 2D-colloidal Coomassie-stained gels were matched by computer-assisted image analysis
34 using ImageMaster 2D Platinum v7.0 software. Phosphorylation index was then calculated as the
35 ratio between the %V of phosphorylated spots on phospho-blot divided by the %V of their
36 respective spots visualized on colloidal Coomassie-stained gels.
37
38

39 All statistical analysis was performed using a two-tailed Student's t-test. $P < 0.05$ was considered
40 statistically significantly different. Protein spots with statistically altered immunoreactivity were
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

1 subjected to mass spectrometry (MS) analysis after excision of the matching spot on the gel stained
2 with colloidal Coomassie [12].
3
4

5 **2. 11. In gel digestion and peptide mass fingerprinting**

6
7 For peptide mass fingerprinting (PMF) electrophoretic spots were manually excised and subjected
8 to in gel digestion by addition of trypsin using an in-gel digestion protocol previously described
9 [13]. Protein identification was carried out by peptide mass fingerprinting (PMF) on an Ultraflex III
10 MALDITOF/TOF mass spectrometer (Bruker Daltonics) equipped with a 200 Hz smartbeam I
11 laser. MS analysis was performed in the positive reflector mode according to defined parameters, as
12 follows: 80 ns of delay; ion source 1: 25 kV; ion source 2: 21.75 kV; lens voltage: 9.50 kV;
13 reflector voltage: 26.30 kV; and reflector 2 voltage: 14.00 kV. The applied laser wavelength and
14 frequency were 353 nm and 100 Hz, respectively, and the percentage was set to 46%. Final mass
15 spectra were produced by averaging 1500 laser shots targeting five different positions within the
16 spot. Spectra were acquired automatically and the Flex Analysis software v3.0 (Bruker) was used
17 for their analysis and for the assignment of the peaks. The applied software generated a list of peaks
18 up to 200, using a signal-to-noise ratio of 3 as the threshold for peak acceptance. Recorded spectra
19 were calibrated using, as the internal standard, peptides arising from trypsin auto-proteolysis. The
20 mass lists were filtered for contaminant removal: mass matrix-related ions, trypsin auto-lysis and
21 keratin peaks. Protein identification by Peptide Mass Fingerprint search was established using
22 MASCOT search engine version 2.1 (Matrix Science, London, UK, <http://www.matrixscience.com>)
23 through the UniProtKB database (<http://www.uniprot.org/>). Taxonomy was limited to Homo
24 sapiens, a mass tolerance of 100 ppm was allowed, and the number of accepted missed cleavage
25 sites was set to one. Alkylation of cysteine by carbamidomethylation was considered a fixed
26 modification, while oxidation of methionine was considered as a possible modification. The criteria
27 used to accept identifications included the extent of sequence coverage, the number of matched
28 peptides, and a probabilistic score of $p < 0.05$. The PMF was performed for three LMW-PTP siRNA
29 2-DE gels, obtaining the same results.
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50

51 **2. 12. RNA Preparation and Quantitative Real Time PCR**

52
53 Total RNA was extracted with RNeasy mini kit (Qiagen). Reverse transcription polymerase first-
54 strand cDNA synthesis was performed by using the iScript cDNA synthesis Kit (Bio-Rad). RT-PCR
55 was performed by using the SsoAdvanced Universal SYBR Green Supermix (BioRad) and specific
56 primers for genes of interest. Primer sequences used for RT-PCR analysis are shown in Table 1.
57 Analyses were performed with Rotor Gene-Q (Qiagen). PCR cycling conditions were: 95 °C for 30
58
59
60
61
62
63
64
65

1 sec, 96 °C for 15 sec, 40 cycles at 60°C. Data were expressed as Ct values and used for the relative
2 quantification of targets with the $\Delta\Delta\text{Ct}$ calculation.
3

4 **3. Results**

5 **3.1. Tyrosine phosphorylation pattern and LMW-PTP**

6
7
8 In order to discover new possible cellular substrates of LMW-PTP in aggressive human tumors, we
9 investigated, by proteomic analysis, the protein phosphorylation pattern of A375 human melanoma
10 cells silenced for LMW-PTP. As a preliminary experiment, we carried out a time course analysis of
11 LMW-PTP protein level, 18, 28 and 36 hours after siRNA administration. With a western blot
12 analysis, we determined that minimal LMW-PTP level was reached 28 h after siRNA transfection
13 (Fig.1). All further experiments were carried out using this timing when the level of LMW-PTP is
14 reduced to 20% with respect to control.
15

16
17
18
19
20
21 Proteomic analysis was performed comparing the protein tyrosine phosphorylation level of LMW-
22 PTP silenced A375 cells with respect to scrambled siRNAs-treated control cells. 2-DE analysis,
23 followed by western blot (Phospho-blot), was performed using anti-phosphotyrosine antibodies.
24 Fig.2 shows representative images of the 2-D phospho-blot obtained from scramble (panel A) and
25 silenced cells (panel B) including the corresponding colloidal Coomassie-stained gels (panel C,
26 scramble, and panel D, silenced). Phospho-blot images were analyzed using ImageMaster 2D
27 Platinum v7.0 software (GE-Healthcare). The normalization of immune-reactive spots was
28 performed against their respective on the colloidal Coomassie-stained 2-DE gel images. We
29 compared normalized-volume percentage values (%V) of spots on phospho-blot of silenced cells
30 with those phospho-blot obtained from scramble cells. Statistical analysis, performed by two-tailed
31 non-paired Student's t-test using Graphpad Prism 6 software, revealed 8 statistically differentially
32 phosphorylated protein spots. These protein spots are circled in Fig.2.
33
34
35
36
37
38
39
40
41
42
43

44 **3.2. Mass spectrometry identification of tyrosine-phosphorylated proteins**

45
46 To identify significant phosphorylated protein spots, we performed preparative 2-DE gels, which
47 were then colloidal Coomassie-stained. The phospho-blot images were matched to the
48 corresponding colloidal Coomassie stained 2-DE gels and the spots corresponding to
49 phosphorylated proteins were cut and subjected to MALDI-TOF mass spectrometry analysis. We
50 successfully identified the eight protein spots whose tyrosine-phosphorylation level was increased
51 in silenced LMW-PTP cells. The results of mass spectrometry identification are reported in Table 1,
52 together with the corresponding spot numbers, score and coverage values of MALDI-TOF analysis,
53 fold change in phosphorylation level and Student t-test p-value. Most of the identified proteins
54
55
56
57
58
59
60
61
62
63
64
65

1 belong to carbohydrate metabolism such as α -enolase (ENO1), pyruvate kinase (PKM2),
2 glyceraldehyde-3-phosphate dehydrogenase (GAPDH) and Triosephosphate isomerase (TPIS). We
3 also found an increase in the tyrosine-phosphorylation level of Annexin A1 (ANXA1) and
4 Prelamin-A/C (LMNA). Concerning LMNA, it was identified in three different protein spots (spot
5 1, 2, 3). These spots display the same molecular weight but differ for the isoelectric point (pI). The
6 observed pI (calculated using Progenesis SameSpots 4.0 software) of spot 2 corresponds to the
7 theoretical pI of LMNA (6.57 by www.uniprot.org). The spot 1 shows an observed pI of 6.38 and
8 the spot 3 of 6.85 thus suggesting the presence of different post-translationally modified forms of
9 LMNA.
10
11
12
13
14
15
16
17

18 3.3. Validation of the proteomic analysis results

19 To confirm that the selected proteins are actually phosphorylated in tyrosine in an LMW-PTP-
20 dependent manner, we performed an immunoprecipitation assay. A375 control cells (transfected
21 with scrambled siRNA) and cells silenced for 28 h with LMW-PTP-specific siRNA, were lysed.
22 Samples were separately immunoprecipitated with antibodies specific for the selected proteins,
23 namely PKM2, ENO1, GAPDH, TPIS, Annexin 1 and Prelamin-A/C. Immunoprecipitated samples
24 were subjected to western blot analysis using anti-phosphotyrosine antibodies, to evaluate the level
25 tyrosine-phosphorylation of the selected proteins. Western blot images were analyzed with Kodak
26 MI software. The results shown in Fig.3 (panels A to F) point out that all the selected proteins are
27 over-phosphorylated when LMW-PTP is silenced, in line with the data obtained by the proteomic
28 analysis.
29
30
31
32
33
34
35
36
37
38
39

40 3.4. LMW-PTP directly interacts with the selected proteins

41 To assess whether the six selected proteins may be substrates of LMW-PTP, we performed a co-
42 immunoprecipitation assays, to evaluate a direct association between LMW-PTP and the putative
43 substrates. To maximize the results, in this experiment we used a different human cell line, the
44 prostate carcinoma DU145. These cells, expressing limited amount of LMW-PTP, were transfected
45 with a vector expressing a dominant-negative form of LMW-PTP(*Dn*) [14] which is a mutant
46 carrying a modification in a critical cysteine residue, present in the active site. This mutant is able to
47 interact with substrates, but it cannot catalyze any tyrosine de-phosphorylation. Lysates of mock-
48 transfected cells and of cells transfected with the *Dn* form of LMW-PTP were subjected to
49 immunoprecipitation with antibodies against the six selected proteins. The immuno-precipitates
50 were analyzed by western blot, using anti-LMW-PTP antibodies. Results are shown in Fig.3, panel
51 G. In the cells overexpressing the dominant negative form of LMW-PTP the interactions are very
52
53
54
55
56
57
58
59
60
61
62
63
64
65

1 strong for all the six selected proteins. The interactions however, are evident, although at a lower
2 extent, also in the mock transfected cells where LMW-PTP level is lower. This fact may indicate
3 that the interaction is quite strong. Based on these evidences we can conclude that the six proteins
4 are *bona fide* substrates of LMW-PTP. To demonstrate the specificity of these results, a co-
5 immunoprecipitation control with an irrelevant antibody (GM130, Santa Cruz Biotechnology SC-
6 16268) was performed. As expected a negative result was achieved (data not shown).
7
8
9

10 11 12 **3.5. LMW-PTP modulates oxidative metabolism in different tumor cell lines.**

13 For further analyses we decided to concentrate our attention on four of the six proteins selected by
14 proteomic analysis involved in glucose metabolism. PKM2, GAPDH, ENO1 and TPIS are in fact
15 all part of the glycolytic pathway, suggesting that LMW-PTP may be involved in the regulation of
16 energetic metabolism in cancer cells. To go deeper in the possible role of LMW-PTP in the
17 oxidative metabolism, we performed several different experiments. First, we evaluated the short-
18 term effects of LMW-PTP downregulation on energetic metabolism of A375 cells. For this purpose,
19 A375 cells were treated with Morin, a LMW-PTP inhibitor that triggers rapid and specific LMW-
20 PTP degradation [7]. After 4 hours of incubation, the A375 cells were analyzed using Seahorse
21 technology. We observed that Morin treatment causes a relevant decrease of glycolytic flux and of
22 oxygen consumption (Fig.4). Based on the above results, we speculate that this effect is in large part
23 due to PKM2 inhibition. Indeed, it is evident that LMW-PTP, hydrolyzing phosphotyrosine
24 residues, contributes to maintain PKM2 in its active form. Conversely, LMW-PTP inhibition or
25 down-regulation favors PKM2 phosphorylation/inhibition, slowing down glycolytic pathway, Krebs
26 cycle, and reducing oxygen consumption rate. Phosphorylated form of PKM2 moves in the nucleus
27 where it stimulates activity of transcription factor HIF-1 α . This promotes transcription of glycolytic
28 genes, contributing to the shift away from oxidative towards glycolytic metabolism. To strengthen
29 the claim that PKM2 phosphorylation pattern is responsible for the observed effects on energy
30 metabolism, we evaluated PKM2 phosphorylation levels after treatment with Morin by
31 immunoprecipitation analysis. The results are reported in the Figure 4 (panel E, F). We found that
32 treatment with Morin increased PKM2 phosphorylation levels, thereby confirming that 4 hours
33 treatment are enough to enhance the phosphorylation status of PKM2.
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52

53 In agreement with this result, we observed a partially different long-term effect due to LMW-PTP
54 silencing: in these conditions cells show an enhanced glycolytic flux, and a high lactate production
55 rate, but they consume lower oxygen and produce lower ROS levels with respect to control cells
56 (Fig. 5). Together, these short and long-term effects support the hypothesis that tumor cells are
57
58
59
60
61
62
63
64
65

1 subjected to metabolic reprogramming after LMW-PTP silencing, enhancing glycolytic flux,
2 probably to compensate for the loss of ATP caused by the OXPHOS inhibition.

3 In order to assess that LMW-PTP effects on energy metabolism are not restricted to the A375 cell
4 line, we repeated the same experiments (as described in Fig. 5, panels A to C) on three different
5 human tumor cell lines. We used PC3 (prostate cancer), HT29 (colon cancer) and MEC-1 (B-cell
6 leukemia) cell lines. In Fig. S1, S2 and S3 we present the results for each cell line. In each panel A
7 we show the effect of LMW-PTP silencing, 28 hours after siRNA administration, demonstrating a
8 comparable efficiency with respect to the A375 cells (see Fig.1). In panels B, C and D respectively
9 we present the evaluation of glucose uptake, lactate production and the rate of oxygen consumption
10 in controls and LMW-PTP silenced cells, demonstrating that the effects are in any case qualitatively
11 identical to those obtained using A375 cells. As far as glucose uptake and lactate production is
12 concerned, a more pronounced effect can be observed for the PC3 cell line with respect to the other
13 cell lines.
14
15
16
17
18
19
20
21
22
23
24

25 **3.6. Action of LMW-PTP on PKM2, GLUT1 and Hexokinase II**

26 It is known that PKM2 may be regulated also in its expression levels [15]. In order to assess how
27 LMW-PTP level may influence glucose utilization, we investigated whether the increase of glucose
28 uptake may be due to enhanced level of the key glycolytic enzyme PKM2. For this purpose, we
29 analyzed the expression level of PKM2 either in A375 cells, silenced or not for the LMW-PTP. The
30 results show that, when LMW-PTP is downregulated with siRNA, the level of PKM2 is higher with
31 respect to control cells (Fig.6, panel A and B). In the same experimental conditions, we also
32 measured the expression level of the GLUT1 glucose transporter. As reported in Fig. 6, a clear
33 increase of GLUT1 level was detected in LMW-PTP silenced A375 cells (Fig.6 panel A and C).
34 Moreover, we investigated variations of the expression level of Hexokinase II, the first rate-limiting
35 enzyme of glycolysis, upon LMW-PTP silencing. The result pointed out a clear increase in
36 Hexokinase II level (Fig.6, panel A and D).
37
38
39
40
41
42
43
44
45
46

47 Pyruvate kinase controls the final and rate-limiting reaction of glycolysis and is present in the cell in
48 different isoforms. In contrast to PKM1, which is present in a constitutively tetrameric active form,
49 PKM2 undergoes conformational conversion between a tetrameric/full active and a dimeric/less
50 active state [16, 17], able to translocate into the nucleus [18, 19]. We have determined whether
51 LMW-PTP silencing may influence also the rate of PKM2 nuclear localization. In cells silenced for
52 LMW-PTP, we can observe that the nuclear amount of PKM2 markedly increases with respect to
53 the cytoplasmic one (Fig.6 panel E).
54
55
56
57
58
59
60
61
62
63
64
65

3.7. Action of LMW-PTP on cell motility

The increase of M2 isoform of pyruvate kinase versus M1 isoform have been correlated with higher cellular proliferation. In fact, PKM2 expression in tumor proliferating cells sustains Warburg metabolism [20, 21], leading to an increase of the glycolytic pathway. For this reason, we evaluated the proliferating rate of A375 cells, transfected either with scramble or LMW-PTP specific siRNA. Fig.7 (panel A) shows that LMW-PTP silencing causes an increase of cell proliferation rate, followed up for 72h after transfection. Since high proliferative and glycolytic cancer cells show a lower EMT phenotype, we decided to analyze the invasiveness of A375 melanoma cells upon LMW-PTP modulation. The results confirmed that, after LMW-PTP silencing, A375 cells are less able to invade through a Matrigel support (panel B), due to a decrease of MMP secretion (panel C). These conditions, as already shown, lead to an increase of glycolytic rate (see results of Fig. 5). To evaluate whether, in A375 cells, LMW-PTP silencing could affect transcription of EMT markers we analysed by using RT-PCR the mRNA expression levels of SNAIL, SLUG. As expected, we found that mRNA level of LMW-PTP strongly decreases 28 hours after transfection (Fig.7 panel D). At the same moment, we found that also mRNA expression levels of SNAIL (panel E), SLUG (panel F) decreased, while expression of E-cadherin mRNA levels increased (panel G). Conversely, no effects were observed after transfection of scramble siRNA. Together, these results demonstrated that LMW-PTP silencing inhibits transcription of key factors involved in EMT, and stimulates expression of E-cadherin, reinforcing data previously reported in this paper.

4. Discussion

In this study, we performed a differential phospho-proteomic analysis of A375 cells, in order to identify possible new LMW-PTP substrates. Although several different substrates have been already defined for this phosphatase, a global analysis was not yet carried out. Moreover, since it is now clear that LMW-PTP over-expression in tumor cells correlates with higher aggressiveness, this analysis was carried out on the A375 human melanoma cell line, derived from a very aggressive tumor, expressing very high level of LMW-PTP. We found that six different proteins result to be over-phosphorylated on tyrosine residues upon LMW-PTP silencing, namely PKM2, GAPDH, α -enolase, TPIS, Lamin, and Annexin A1. For all the six selected proteins, it was possible to assess that it exists a direct molecular contact with the phosphatase, strongly suggesting that they are bona fide LMW-PTP substrates. Interestingly, our data show that four out of six of the new putative LMW-PTP substrates are glycolytic enzymes. These evidences suggest that LMW-PTP could have a key role in regulating the glycolytic pathway, probably by modulating the phosphorylation status of these enzymes.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

As far as PKM2 is concerned, it is already known that the activity of this enzyme is modulated by tyrosine phosphorylation. The tyrosine-phosphatase PTP1B, in fact, is capable to de-phosphorylate PKM2 on Tyr-105 and Tyr-148 [22]. In the present work, to our knowledge for the first time, we suggest that also LMW-PTP acts on PKM2, de-phosphorylating this enzyme on tyrosine. The identity of the tyrosine/s involved in the mechanism remains to be elucidated.

GAPDH is tyrosine phosphorylated by Src [23] but, to our knowledge, nothing is known about the mechanism of its de-phosphorylation. On the other hand, phosphorylation of α -enolase has been associated with pancreatic cancer and leads to the production of specific auto-antibodies in pancreatic ductal adenocarcinoma patients, with diagnostic value [24]. In the case of α -enolase both kinase and phosphatase activity involved in this mechanism are not known. Finally, several evidences have demonstrated that TPIS is phosphorylated on Serine residue by Cdk2 [25], but, to our knowledge, no regulation via tyrosine phosphorylation has been yet identified. For all these three proteins, namely GAPDH, α -enolase and TPIS, our results suggest that they may be tyrosine-phosphorylated and that LMW-PTP may catalyze their tyrosine de-phosphorylation.

In addition, two other proteins, Annexin A1 and Lamin, not involved in glycolysis, has been identified by our proteomic analysis. Annexin A1 have been implicated in many cellular processes such as inflammation [26, 27, 28], glucocorticoid action [29], secretion and exocytosis [30, 31, 32], cell growth and differentiation [33, 34, 35] and phosphorylated by several protein tyrosine kinase (PTKs) [36, 37]. As far as Lamin is concerned, its phosphorylation is mainly dependent on the cell cycle [38, 39, 40]. Our results indicate that both Annexin A1 and Lamin may be subjected to LMW-PTP-dependent tyrosine de-phosphorylation.

The fact that, among the six proteins selected with proteomic analysis, four of them are enzymes essential for glycolytic pathway suggests that LMW-PTP could be involved in the regulation of energetic metabolism of cancer cell. It is important to remember that, in many tumor cells and tissues, LMW-PTP is generally over-expressed with respect to normal cells [2, 4, 6, 7]. For these reasons, we decided to concentrate our attention on the LMW-PTP-dependent modulation of glucose catabolism. To evaluate short- and long-term effects of LMW-PTP inhibition, we studied metabolic profile of A375 cells treated with Morin or silenced for LMW-PTP. We previously demonstrated that the treatment with Morin causes the fast downregulation of LMW-PTP expression levels [7], while silencing deprives A375 cells of LMW-PTP for longer time. Thus, cells treated with Morin represent a model for study the acute effects of LMW-PTP inhibition, whereas silenced cells were studied to evaluate the long-term effects of LMW-PTP deprivation on energetic metabolism of cells. We found that after treatment with Morin, both glycolysis and oxygen consumption of A375 cells decrease. We speculate that this effect is in large part due to LMW-PTP

1 inhibition, which leads a fast PKM2 phosphorylation/inactivation. **This hypothesis was confirmed**
2 **by PKM2 immunoprecipitation analysis.** Due to decrease of PKM2 activity, the glycolytic flow
3 slows down, and pyruvate production falls, thereby impairing Krebs cycle, electron chain transport,
4 oxygen consumption, and ATP production. If maintained for relatively long time, a similar
5 metabolic asset could impair cell survival, or induce cell death. However, we clearly demonstrated
6 that silenced cells undergo metabolic rewiring, enhancing glucose uptake and lactate production,
7 but maintain a low oxygen consumption and producing low ROS levels respect to unsilenced cells.
8 Moreover, we observed that silenced cells express high levels of the glucose transporter GLUT1,
9 and hexokinase II, the first rate-limiting enzyme of glycolysis. Taken together, these results
10 demonstrate that silenced cells acquire an evident Warburg metabolism. From a mechanistic point
11 of view, PKM2 strongly contributes to conversion of A375 cells from a respiratory toward a
12 glycolytic phenotype. Indeed, we found that PKM2 expression levels increased in A375 silenced
13 cells respect to parental cells, and that silenced cells contain higher amounts of phosphorylates
14 PKM2. Finally, we observed that LMW-PTP silencing favors migration of PKM2 dimeric form into
15 the nucleus (see **Fig.6**, panel E). These evidences are in line with previous findings showing that the
16 phosphorylated/dimeric form of PKM2 is able to migrate into the nucleus, were it acts as a
17 transcriptional co-activator of β -catenin and hypoxia-inducible factor 1 α (HIF-1 α), one the master
18 regulator of Warburg metabolism [18, 19, 41]. In synthesis, we demonstrate that in melanoma cells
19 the overexpression of LMW-PTP is functional to maintain PKM2 in its dephosphorylate status – the
20 tetrameric, “full active” form - which is retained in the cytoplasm, where it converts PEP in
21 pyruvate, thereby fueling Krebs cycle and OXPHOS.
22

23 Similar effects were observed also in other cancer cells such as prostate cancer PC3, colon cancer
24 HT29 and MEC-1 from B-cell leukemia, thereby confirming that this behavior is not a specific
25 characteristic of the A375 melanoma cell line but, rather, represent a general feature of cancer cells
26 expressing high LMW-PTP levels.
27

28 Considering that high LMW-PTP expression levels were found in most of aggressive cancer cells,
29 we argue that its presence offers some advantage to cancer cells.
30

31 Based on data reported in this paper, we can exclude that high level of expression of LMW-PTP
32 confers some vantages in term of growth rate. Rather, we observe that high level of expression of
33 LMW-PTP enhance cell motility and invasiveness. A375, together with the other cell lines used in
34 this work, show an aggressive phenotype, and a relative strong resistance to traditional anticancer
35 drugs. We have already demonstrated that pharmacological inhibition of LMW-PTP increases
36 sensitivity of melanoma, and PC3 to dacarbazine, 5-FU and radiotherapy [7]. Similar results were
37 reported by others, in a study conducted on colon cancer cells [6]. Together, these evidences
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

1 suggest that LMW-PTP could be involved in the acquisition of an aggressive phenotype, rather than
2 stimulate growth rate of cancer cells. The exact mechanism that link LMW-PTP expression, PKM2
3 activation and resistance to apoptosis remains to be clarified.
4

5 **4.1. Conclusions**

6
7 In this work we can clearly assess that high LMW-PTP expression, which is common in tumor
8 cells, negatively influences the rate of glycolysis. This regulation is very probably due to the fact
9 that LMW-PTP modulate the tyrosine phosphorylation level of at least four different enzymes
10 involved in glycolysis. Moreover, we show that changes in expression levels of LMW-PTP leads to
11 the control of invasiveness and cell proliferation rate.
12
13
14

15
16 Much more work is needed to precisely understand the consequences of tyrosine phosphorylation
17 control at the level of the proteins that we have identified as new LMW-PTP substrates.
18
19
20
21
22

23 **Funding**

24
25 Istituto Toscano Tumori (Messori-ITT-2015)

26
27 Fondi di Ateneo-University of Florence – Italy

28
29 PP acknowledges AIRC (Associazione Italiana per la Ricerca sul cancro) for the project “Assaying
30 tumor metabolic deregulation in live cells”; project code 19515.
31
32
33

34 **Conflict of interest**

35
36 The authors have no conflicts of interest to declare.
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

5. References

- [1] P. Chiarugi, M.L. Taddei, N. Schiavone, L. Papucci, E. Giannoni, T. Fiaschi, S. Capaccioli, G. Raugei, G. Ramponi, LMW-PTP is a positive regulator of tumor onset and growth, *Oncogene*, 23 (2004) 3905-14.
- [2] F. Malentacchi, R. Marzocchini, S. Gelmini, C. Orlando, M. Serio, G. Ramponi, G. Raugei, Up-regulated expression of low molecular weight protein tyrosine phosphatases in different human cancers, *Biochem Biophys Res Commun.* 334 (2005) 875-83.
- [3] R. Marzocchini, F. Malentacchi, M. Biagini, D. Cirelli, C. Luceri, G. Caderni, G. Raugei, The expression of low molecular weight protein tyrosine phosphatase is up-regulated in 1,2-dimethylhydrazine-induced colon tumours in rats, *Int J Cancer.* 122 (2008) 1675-8.
- [4] R.R. Ruela-de-Sousa, E. Hoekstra, A.M. Hoogland, K.C. Queiroz, M.P. Peppelenbosch, A.P. Stubbs, K. Pelizzaro-Rocha, G.J. van Leenders, G. Jenster, H. Aoyama, C.V. Ferreira, G.M. Fuhler, Low-Molecular-Weight Protein Tyrosine Phosphatase Predicts Prostate Cancer Outcome by Increasing the Metastatic Potential, *Eur Urol.* 69 (2016) 710-9.
- [5] P.A. Ferreira, R.R. Ruela-de-Sousa, K.C. Queiroz, A.C. Souza, R. Milani, R.A. Pilli, M.P. Peppelenbosch, J. den Hertog, C.V. Ferreira, Knocking down low molecular weight protein tyrosine phosphatase (LMW-PTP) reverts chemoresistance through inactivation of Src and Bcr-Abl proteins, *PLoS One*, 7 (2012) 44312.
- [6] E. Hoekstra, L.L. Kodach, A.M. Das, R.R. Ruela-de-Sousa, C.V. Ferreira, J.C. Hardwick, C.J. van der Woude, M.P. Peppelenbosch, T.L. Ten Hagen, G.M. Fuhler, **Low molecular weight protein tyrosine phosphatase (LMWPTP) upregulation mediates malignant potential in colorectal cancer**, *Oncotarget* 6 (2015) 8300-12.
- [7] G. Lori, P. Paoli, A. Caselli, P. Cirri, R. Marzocchini, M. Mangoni, C. Talamonti, L. Livi, G. Raugei, Targeting LMW-PTP to sensitize melanoma cancer cells toward chemo- and radiotherapy, *Cancer Medicine*, (2018) doi: 10.1002/cam4.1435
- [8] P. Chiarugi, P. Cirri, F. Marra, F. G. Raugei, G. Camici, G. Manao, G. Ramponi, G. LMW-PTP is a negative regulator of insulin-mediated mitotic and metabolic signaling, *Biochem Biophys Res Commun.* 1997 238 (1997) 676-82.
- [9] S.M. Stanford, A.E. Aleshin, V. Zhang, R.J. Ardecky, M.P. Hedrick, J. Zou, S.R. Ganji, M.R. Bliss, F. Yamamoto, A.A. Bobkov, J. Kiselar, Y. Liu, G.W. Cadwell, S. Khare, J. Yu, A. Barquilla, T.D.Y. Chung, T. Mustelin, S. Schenk, L.A. Bankston, R.C. Liddington, A.B. Pinkerton, N. Bottini, Diabetes reversal by inhibition of the low-molecular-weight tyrosine phosphatase, *Nat Chem Biol.* 13 (2017) 624-632.
- [10] A.V. Faria, T.F. Tornatore, R. Milani, K.C.S. Queiroz, I.H. Sampaio, E.M.B. Fonseca, K.J.P. Rocha-Brito, T.O. Santos, L.R. Silveira, M.P. Peppelenbosch, C.V. Ferreira-Halder, Oncophosphosignaling Favors a Glycolytic Phenotype in Human Drug Resistant Leukemia, *J Cell Biochem.* 118 (2017) 3846-3854.

- 1
2
3 [11] A. Caselli, P. Paoli, A. Santi, C. Mugnaioni, A. Toti, G. Camici, P. Cirri, Low molecular weight protein
4 tyrosine phosphatase: Multifaceted functions of an evolutionarily conserved enzyme, *Biochim Biophys Acta*
5 1864 (2016) 1339-55.
6
7 [12] P. Chiarugi, P. Cirri, G. Raugei, G. Camici, F. Dolfi, A. Berti, G. Ramponi, PDGF receptor as a specific
8 in vivo target for low M(r) phosphotyrosine protein phosphatase, *FEBS Lett.* 372 (1995) 49-53.
9
10 [13] A. Carpentieri, T. Gamberi, A. Modesti, A. Amoresano, B. Colombini, M. Nocella, M.A. Bagni, T.
11 Fiaschi, L. Barolo, M. Gulisano, F. Magherini, Profiling Carbonylated Proteins in Heart and Skeletal Muscle
12 Mitochondria from Trained and Untrained Mice, *J Proteome Res.* 15 (2016) 3666-3678.
13
14
15 [14] T. Gamberi, T. Fiaschi, E. Valocchia, A. Modesti, P. Mantuano, J.F. Rolland, F. Sanarica, A. De Luca,
16 F. Magherini, Proteome analysis in dystrophic mdx mouse muscle reveals a drastic alteration of key
17 metabolic and contractile proteins after chronic exercise and the potential modulation by anti-oxidant
18 compounds, *J Proteomics*, 170 (2018) 43-58.
19
20
21 [15] W. Yanga, Z. Lua, Regulation and function of pyruvate kinase M2 in cancer, *Cancer Lett.* 339 (2013)
22 153–158.
23
24
25 [16] D. Anastasiou, Y. Yu, W.J. Israelsen, J.K. Jiang, M.B. Boxer, B.S. Hong BS, W. Tempel, S. Dimov, M.
26 Shen, A. Jha, H. Yang, K.R. Mattaini, C.M. Metallo, B.P. Fiske, K.D. Courtney, S. Malstrom, T.M. Khan, C.
27 Kung, A.P. Skoumbourdis, H. Veith, N. Southall, M.J. Walsh, K.R. Brimacombe, W. Leister, S.Y. Lunt,
28 Z.R. Johnson, K.E. Yen, K. Kunii, S.M. Davidson, H.R. Christofk, C.P. Austin, J. Inglese, M.H. Harris, J.M.
29 Asara, G. Stephanopoulos, F.G. Salituro, S. Jin, L. Dang, D.S. Auld, H.W. Park, L.C. Cantley, C.J. Thomas,
30 M.G. Vander Heiden, Pyruvate kinase M2 activators promote tetramer formation and suppress
31 tumorigenesis, *Nat Chem Biol.* 8 (2012) 839–847.
32
33
34 [17] X. Gao, H. Wang, J.J. Yang, X. Liu, Z.R. Liu, Pyruvate kinase M2 regulates gene transcription by
35 acting as a protein kinase, *Mol Cell.* 45 (2012) 598–609.
36
37
38 [18] W. Luo, H. Hu, R. Chang, J. Zhong, M. Knabel, R. O’Meally, R.N. Cole, A. Pandey, G.L. Semenza,
39 Pyruvate kinase M2 is a PHD3-stimulated coactivator for hypoxia-inducible factor 1^α; *Cell.*; (2011);
40 145:732–744.
41
42
43 [19] W. Yang, Y. Xia, H. Ji, Y. Zheng, J. Liang, W. Huang, X. Gao, K. Aldape, Z. Lu, Nuclear PKM2
44 regulates beta-catenin transactivation upon EGFR activation, *Nature*, 480 (2011) 118–122.
45
46
47 [20] I. Samudio, M. Fiegl, M. Andreeff, Mitochondrial uncoupling and the Warburg effect: molecular basis
48 for the reprogramming of cancer cell metabolism, *Cancer Res.* 69 (2009) 2163–6.
49
50
51 [21] W.H. Koppenol, P.L. Bounds, C.V. Dang, Otto Warburg’s Contributions to current concepts of cancer
52 metabolism, *Nat. Rev. Cancer.* 2011; 11 (2011) 325–37.
53
54
55
56
57
58
59
60
61
62
63
64
65

- 1 [22] A. Bettaieb, J. Bakke, N. Nagata, K. Matsuo, Y. Xi, S. Liu, D. AbouBechara, R. Melhem, K. Stanhope,
2 B. Cummings, J. Graham, A. Bremer, S. Zhang, C.A. Lyssiotis, Z.Y. Zhang, L.C. Cantley, P.J. Havel, F.G.
3 Haj, Protein tyrosine phosphatase 1B regulates pyruvate kinase M2 tyrosine phosphorylation, *J Biol Chem.*
4 288 (2013) 17360-71.
5
6
7 [23] E.J. Tisdale, C.R. Artalejo, A GAPDH Mutant Defective in Src-Dependent Tyrosine Phosphorylation
8 Impedes Rab2-Mediated Events, *Traffic*, 8 (2007) 733–741.
9
10
11 [24] B. Tomaino, P. Cappello, M. Capello, C. Fredolini, I. Sperduti, P. Migliorini, P. Salacone, A. Novarino ,
12 A. Giacobino, L. Ciuffreda, M. Alessio, P. Nisticò, A. Scarpa, P. Pederzoli, W. Zhou, E.F. Petricoin Iii, L.A.
13 Liotta, M. Giovarelli, M. Milella, F. Novelli, Circulating autoantibodies to phosphorylated α -enolase are a
14 hallmark of pancreatic cancer, *Journal of Proteome Research*, 10 (2011) 105–112.
15
16
17
18 [25] W.H. Lee, J.S. Choi, M.R. Byun, K.T. Koo, S. Shin, S.K. Lee, Y.J. Surh, Functional inactivation of
19 triosephosphate isomerase through phosphorylation during etoposide-induced apoptosis in HeLa cells:
20 potential role of Cdk2, *Toxicology*, 278 (2010) 224-8.
21
22
23
24 [26] G. Cirino, R.J. Flower, Human recombinant lipocortin I inhibits prostacyclin production by human
25 umbilical artery in vitro, *Prostaglandins*, 34 (1987) 59-62.
26
27
28 [27] M. Perretti, Lipocortin I and chemokine modulation of granulocyte and monocyte accumulation in
29 experimental inflammation, *Gen. Pharmacol.* 31 (1998) 545-552.
30
31
32 [28] F. Carey, R. Forder, M.D. Edge, A.R. Greene, M.A. Horan, P.J. Strijbos, N.J. Rothwell, Lipocortin I
33 fragment modifies pyrogenic actions of cytokines in rats, *Am. J. Physiol.* 259 (1990) 266-269.
34
35
36 [29] W.T. Wong, S.C. Frost, H.S. Nick, Protein-synthesis-dependent induction of annexin I by
37 glucocorticoid, *Biochem. J.* 275 (1992) 313-319.
38
39
40 [30] R.D. Burgoyne, Calpactin in exocytosis, *Nature*, 331 (1988) 20.
41
42
43 [31] M. Ohnishi, M. Tokuda, T. Masaki, T. Fujimura, Y. Tai, T. Itano, H Matsui, T. Ishida, R, Konishi, J.
44 Takahara, O. Hatase, Involvement of Annexin I in glucose-induced insulin secretion in rat pancreatic islets,
45 *Endocrinology*, 136 (1995) 2421-2426.
46
47
48 [32] J.C. Buckingham, R.J. Flower, Lipocortin I: A second messenger of glucocorticoid action in the
49 hypothalamo-pituitary-adrenocortical axis, *Mol. Med. Today* 3 (1997) 296-302.
50
51
52 [33] J.F. Tait, M. Sakata, B.A. McMullen, C.H. Miao, T. Funakoshi, L.E. Hendrickson, K. Fujikawa,
53 Placental anticoagulant proteins: Isolation and comparative characterization four members of the lipocortin
54 family, *Biochemistry*, 27 (1988) 6268-6276.
55
56
57
58 [34] F. William, B. Mroczkowski, S. Cohen, A.S. Kraft, Differentiation of HL-60 cells is associated with an
59 increase in the 35-kDa protein lipocortin I, *J. Cell. Physiol.* 137 (1988) 402-410.
60
61
62
63
64
65

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
- [35] M.T. Fox, D.A. Prentice, J.P. Hughes, Increase in p11 and annexin II proteins correlate with differentiation in the PC12 pheochromocytoma, *Biochem. Biophys. Res. Commun.* 177 (1991) 1188-1193.
- [36] E. Erikson, R.L. Erikson, Identification of a cellular protein substrate phosphorylated by the avian sarcoma virus-transforming gene product, *Cell* 21 (1980) 829-836.
- [37] R.A. Fava, S. Cohen, Isolation of a calcium-dependent 35-kilodalton substrate for the epidermal growth factor receptor/kinase from A-431 cells, *J. Biol. Chem.* 259 (1984) 2636-2645.
- [38] B. Lüscher, L. Brizuela, D. Beach, R.N. Eisenman, A role for the p34cdc2 kinase and phosphatases in the regulation of phosphorylation and disassembly of lamin B2 during the cell cycle, *EMBO J* 1991.
- [39] Y. Ottaviano, L. Gerace, Phosphorylation of the nuclear lamins during interphase and mitosis, *J. Biol. Chem.* 260 (1985) 624-32.
- [40] R. Rzepecki, P.A. Fisher, In vivo phosphorylation of drosophila melanogaster nuclear lamins during both interphase and mitosis, *Cell. Mol. Biol. Lett.* 7 (2002) 859-76.
- [41] E. Giannoni, M.L. Taddei, a. Morandi, G. Comit, M. Calvani, F. Bianchini, B. Richichi, G. Raugei, N. Wong, D. Tang, P. Chiarugi, Targeting stromal-induced pyruvate kinase M2 nuclear translocation impairs oxphos and prostate cancer metastatic spread, *Oncotarget*, 6 (2015) 24061-74.

Figure captions

1
2
3 **Fig.1 A375 human melanoma cells silenced for LMW-PTP.** Transfection time course: A375
4 cells were silenced with siRNA or scramble (20nM). Western blots were conducted at 18 h, 28 h
5 and 36 h after transfection. In panel A, a representative experiment is shown. In panel B, a
6 densitometric analysis is presented as result of three independent experiments.
7
8
9

10
11
12 **Fig.2 Representative 2-D phospho-blots and Colloidal Coomassie stained gels of cells silenced**
13 **for LMW-PTP cells and of control cells.** Sample proteins from control (A) and LMW-PTP-
14 silenced cells (B) were separated by IEF (11 cm, 3–10 NL). Second dimension was performed in 9–
15 16% polyacrylamide linear gradient and phosphorylated proteins were detected by western blot. In
16 panel, (C) and (D) the corresponding colloidal Coomassie stained gels are shown. For each cell
17 specimen (LMW-PTP-silenced cells and control cells), six colloidal Coomassie-stained gels and six
18 2-D phospho-blots were performed. Statistical analysis was carried out by ImageMaster 2D
19 Platinum software v7.0 (GE Healthcare) using a two-tailed Student's t-test. Circles and numbers
20 indicate the statistical differentially phosphorylated spots ($p < 0.05$) identified by MS.
21
22
23
24
25
26
27
28
29
30

31 **Fig.3 Validation of novel substrates of LMW-PTP using immuno and co-immunoprecipitation.**
32 (A-F) Immunoprecipitation analysis of α -Enolase, PKM2, GAPDH, TPIS, Annexin A1 and Lamin
33 A/C using appropriate antibodies. Samples were subjected to SDS-PAGE and analyzed by Western
34 Blotting using 4G10 anti-pTyr antibodies. For each co-immunoprecipitation, western blot with the
35 antibodies for PKMM1, ENO1, GAPDH, TPIS, Annexin 1 and prelamin-A/C was performed. In the
36 histograms the quantification is shown, as phosphorylated form of the protein/ total protein. (G) Co-
37 immunoprecipitation analysis of PKM2, α Enolase, GAPDH, TPIS, Annexin A1 and Lamin A/C
38 using anti-LMW-PTP antibody. DU145 cells mock-transfected or transfected with the *Dn* form of
39 LMW-PTP were used. Co-immunoprecipitation control with an irrelevant antibody (GM130, Santa
40 Cruz Biotechnology SC-16268) gave negative results (data not shown).
41
42
43
44
45
46
47
48
49
50

51 **Fig.4 Energetic profile of A375 cells treated with Morin.** Cells were starved for 16 hours and
52 then incubated for further 4 hours at 37°C in the presence of starvation medium containing (open
53 circles), or not (black circles), 50 μ M Morin. After, cells were washed with PBS and then analysed
54 by using Seahorse technology (Agilent Technologies Inc., US). (A), oxygen consumption rate; (B),
55 extracellular acidification rate; (C), OCR/ECAR ratio in basal condition; (D), maximal respiration
56 determined after treatment of A375 cells with FCCP. Data reported in the figure represent the mean
57
58
59
60
61
62
63
64
65

values \pm S.D. (n = 8) ** p < 0.05; *** p < 0.001; **(E-F)** Immunoprecipitation analysis of PKM2 phosphorylation levels after treatment with Morin. PKM2 was immunoprecipitated and analysed by SDS-PAGE separation and western blot. Equivalent amount of total protein was loaded on gels. Phosphorylation status on tyrosine residue of PKM2 was detected by using monoclonal 4G10 anti-phosphotyrosine antibodies (Millipore). The experiment was carried out in duplicate. **(E)** representative western blot analysis; **(F)** Images were acquired by using Amersham Imager 600 luminometer (Amersham). Quantification of bands was carried out by using the Amersham quantification software. Data reported in the figure represent the mean value \pm S.E.M. (n = 2).

Fig.5 LMW-PTP silencing induces metabolic switch in A375 human melanoma cells. All the experiments were performed on A375 cells, 28 h after transfection. **(A)** Glucose uptake. Cells were incubated with (U-¹⁴C) deoxy-D-Glucose and then lysed with 0.1M NaOH. The amount of up-taken glucose was measured using a scintillator analyzer. **(B)** Lactate production. The medium of silenced and control cells was collected, and lactate amount was measured using a commercial kit. **(C)** Oxygen consumption. The rate of O₂ consumption was evaluated using a Clark-type O₂ electrode from Hansatech. Values obtained for three independent experiments were normalized on cells number. **(D)** ROS level. Intracellular ROS level were measured using ROS detection assay (DCFDA).

Fig.6 LMW-PTP is involved in the regulation of key-glycolytic enzymes: A375 cells were transfected with siRNA or scramble. **(A)** After 24h cells were lysed and analyzed by western blot with specific primary antibody against PKM2, GLUT1 and HKII. **(B, C, D)** Densitometric analysis were obtained using actin as internal control. **(E)** Melanoma transfected cells were subjected to nuclear extraction, as described in Methods, to measure the amount of cytosolic and nuclear form of PKM2. To assess the grade of this purification, actin content, in both compartment, was evaluated.

Fig.7 LMW-PTP affects cell growth and invasiveness of A375 melanoma cells. **(A)** A375 cells were transfected with siRNA or scramble. After 24, 48 and 72h cells were detached and counted with a Burker chamber, using contrast phase microscope. The invasive ability of Melanoma silenced cells was determined using Boyden chamber assay **(B)** and measuring MMP2 activity in a gel zymography **(C)**. After 28h of scramble or siRNA transfection, total RNA was extracted, and mRNA levels of LMW-PTP, SLUG, SNAIL and E-cadherin were determined with RT-PCR **(D-G)**.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
Fig.S1 LMW-PTP regulates metabolism of PC3 prostate cancer cells. (A) PC3 cells, 28h after siRNA or scramble transfection, were lysed and analysed by western blotting to validate LMW-PTP silencing. Actin was used as internal control for densitometric analysis. (B) Glucose uptake. PC3 cells were incubated with (U-14C) deoxy-D-Glucose for 30 minutes, then washed twice with cold PBS and lysed with 0.1M NaOH. The amount of radioactive up-taken glucose from the cells was measured using a scintillator analyzer. All values were normalized to protein content. (C) Lactate production. The medium of silenced and control cells was collected, and lactate amount was measured using a commercial kit. L-Lactate content was normalized to protein content. (D) Oxygen consumption, 28h after silencing, were carried using a Clark-type O₂ electrode from Hansatech.

18
19
20
21
22
23
24
25
26
Fig.S2 LMW-PTP regulates metabolism of HT29 colon cancer cells: The experiments were performed on the HT29 colon cancer cell line, as described in Fig. S1. (A) validation of LMW-PTP silencing by western blot. (B) Glucose uptake. (C) Lactate production. (D) Oxygen consumption, 28h after silencing, were carried using a Clark-type O₂ electrode from Hansatech.

27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
Fig.S3 LMW-PTP regulates metabolism of MEC-1 chronic B leukemia cells. The experiments were performed on the MEC-1 colon cancer cell line, as described in Fig. S1. (A) validation of LMW-PTP silencing by western blot. (B) Glucose uptake. (C) Lactate production. (D) Oxygen consumption, 28h after silencing, were carried using a Clark-type O₂ electrode from Hansatech.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49

Table 1: Differentially tyrosine-phosphorylated proteins identified by MALDI-TOF mass spectrometry.

| Spot n. ^a | Protein | AC ^b | Gene | GO Biological Process ^c | Mascot search results | | | p-value ^g | Fold change siRNA vs control ^h |
|----------------------|-----------------|-----------------|-------|--|-----------------------|----------------------------|--------------------------------|----------------------|---|
| | | | | | Score ^d | Matched Pept. ^e | Seq. coverage (%) ^f | | |
| 1 | Prelamin-A/C | P02545 | LMNA | Establishment or maintenance of microtubule cytoskeleton polarity GO:003095 | 96 | 14/50 | 22 | 0.0066 | 1.5 |
| 2 | Prelamin-A/C | P02545 | LMNA | Establishment or maintenance of microtubule cytoskeleton polarity GO:003095 | 130 | 18/34 | 27 | 0.005 | 1.5 |
| 3 | Prelamin-A/C | P02545 | LMNA | Establishment or maintenance of microtubule cytoskeleton polarity GO:003095 | 155 | 22/47 | 31 | 0.001 | 3.2 |
| 4 | Alpha-enolase | P06733 | ENO1 | Canonical glycolysis GO:0061621 | 158 | 18/43 | 24 | 0.0009 | 2.2 |
| 5 | Pyruvate kinase | P14618 | PKM | Canonical glycolysis GO:0061621 | 204 | 30/83 | 61 | <0.0001 | 2.8 |
| 6 | Annexin A1 | P04083 | ANXA1 | Cell-cell adhesion GO:0098609 Negative | 137 | 13/38 | 42 | 0.0009 | 2.9 |

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49

| | | | | | | | | | |
|----------|--|--------|-------|---|-----|-------|----|---------|-----|
| | | | | regulation of apoptotic process GO:0043066 | | | | | |
| 7 | Glyceraldehyde-3-phosphate dehydrogenase | P04406 | GAPDH | Canonical glycolysis GO:0061621 | 178 | 16/45 | 29 | 0.0003 | 1.8 |
| 8 | Triosephosphate isomerase | P60174 | TPIS | Canonical glycolysis GO:0061621 | 110 | 14/40 | 38 | <0.0001 | 2 |

^a Spot numbers match those reported in the representative 2-DE images shown in Fig.2.

^b Accession number in Swiss-Prot/UniprotKB (www.uniprot.org/).

^c Functional categories based on the Gene Ontology (GO) terms related to their major biological process using Nextprot database (<https://www.nextprot.org/>), data release 2017-08-01 Application release v2.10.0.

^d MASCOT MS score (Matrix Science, London, UK; <http://www.matrixscience.com>). MS matching score greater than 56 was required for a significant MS hit (p -value<0.05).

^e Number of matched peptides corresponds to peptide masses matching the top hit from Ms-Fit PMF, searched peptide are also reported.

^f Sequence coverage = (number of the identified residues/total number of amino acid residues in the protein sequence) x100%.

^g The p-value listed is the significance of altered phosphorylation levels relative to control samples with $p < 0.05$.


^h Fold change (siRNA PTP vs control) was calculated dividing the phosphorylation index (see methods for details) of siRNA PTP cells with that of control cells.

Table 2: Primer sequence utilized for RT-PCR.

| GENE | FORWARD (5' to 3') | REVERSE (3' to 5') |
|-------------------|---------------------------------|--------------------------------|
| LMW-PTP | GGAAACTTGTAACCGATCAAAACA | CCCACGTTCCAGTCAGAAACA |
| SNAIL | GCTGCAGGACTCTAATCCAGAGTT | GACAGAGTCCCAGATGAGCATTG |
| SLUG | AGATGCATATTCGGACCCAC | CCTCATGTTTGTGCAGGAGA |
| E-Cadherin | CAGCCCAAAGTGTGTGAGAA | TGTGATGTTGGCCGTGTTAT |
| GAPDH | GGACCTGACCTGCCGTCTAGAA | GGTGTGCTGTTGAAGTCAGAG |

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

Figure 1



B




Figure 2




Figure 3




Figure 4




Figure 5







Figure 6




Figure 7





Figure S1

[Click here to download high resolution image](#)








Figure S3


[Click here to download high resolution image](#)




B



C



D



Supplementary Material (for review purposes only)**Response to reviewer 2.**

Query 6: *Figure 3G: it would be nice to show that precipitation with an irrelevant antibody does not precipitate LMWPTP.*

Response 6: As suggested by reviewer, we have performed an experiment, using antibodies against GM-130 (P-20) (Santa Cruz Biotechnology SC-16268). GM 130 is a cis-Golgi matrix protein involved in vesicle tethering to Golgi membrane. Until now, no data about the interaction between GM130 and LMW-PTP was reported or published before. As showed in Figure 1 (Supplemental material for reviewers), any signal was visible after probing membrane with LMW-PTP antibodies, confirming that the interaction between PKM2 and LMW-PTP is specific. Finally, to highlight this result, we have added a sentence in Figure 3 caption.


Figure Query 6

Figure Query 6: Co-immunoprecipitation analysis. A375 cells, expressing or not the dominant negative of LMW-PTP, were lysed and incubated with PKM2 or GM130 antibodies overnight. The protein A was used to precipitate antibodies and the precipitates were collected and analyzed by western blot. Membranes were probed with antibodies anti-LMW-PTP in order to verify the specificity of interaction.

Query 7: *The authors use Morin to inhibit LMWPTP, but they have themselves shown that this compound also inhibits PTP1B and TC-PTP with a lower IC50. (Cancer Med. 2018 May; 7(5): 1933-1943). Thus, PTP1B may also be involved in the results in Figure 4 and the differences between Figure 4 and Figure 5. Furthermore, cells were starved in Figure 4, and not in Figure 5, which hampers comparison. Is it not possible to treat cells longer with Morin, for a better comparison?*


Response 7: As suggested by reviewer, we performed a test with Seahorse XF analyzer incubating A375 cells with Morin for 24 hours before the analysis. The standard protocol used for Seahorse analysis forecasts seeding and treatment of cells in the same moment. Unfortunately, we observed that, after 24 hours incubation, most of cells were suffering or undergoing death. As consequence, data obtained resulted not to be comparable with the ones obtained incubating Morin for 4 hours.

Based on this evidence, we decided to change protocol, using compound 23 a novel LMW-PTP specific inhibitor (see ref. 9 of this paper, Stanford et al., 2017) to carried out a further test. In our opinion, this compound enables us to address both requests of reviewer. First, this compound is a specific inhibitor of LMW-PTP. Moreover, this compound can be used in standard growth


conditions (complete medium with FBS instead of starvation medium), enabling us to obtain data comparable with that reported in the Figure 5. Results of new experiments were reported in the Figure 2. The results of experiment carried out after 4 hours incubation, show that the treatment with compound 23 decreases basal OCR, without affecting basal ECAR. These results are in total agreement with data obtained using Morin and, suggest that data reported in the Figure 4 are really due to LMW-PTP inhibition and not to inhibition of PTP1B. A similar test was carried out incubating A375 cells in the presence of compound 23 for 24 hours. Likewise, the test carried out with Morin, we observed that most of cells are suffering or death. This evidence suggests that a technical problem prevents obtaining reproducible and analyzable results after 24-hours incubation both with Morin or compound 23. Actually, we would like not to show these results in the present paper, since a new manuscript is in preparation, concerning compound 23, in the frame of a collaboration with Dr. Bottini's group.

Figure Query 7.

A



B



C




Figure Query7: Seahorse analysis of A375 cells treated with compound 23 for 4 hours. (A), oxygen consumption rate (OCR); (B) extracellular acidification rate (ECAR); (C), OCR/ECAR ratio in basal condition

***Conflict of Interest form**

[Click here to download Conflict of Interest form: coi_disclosure.pdf](#)